Researchers conducted a scoping review of 147 studies to map the molecular structure of carrier-free self-assembled nanodrugs used in cancer treatment. They found that these drugs are primarily organized into two types: covalent prodrug assemblies and noncovalent multi-active co-assemblies. While these structures are diverse, the study found no clear link between the specific molecular architecture and how well the drugs overcome certain resistance levels.
Despite the potential of these nanodrugs, the review identified several gaps in the current research. Only 3 studies reported on batch consistency and scalability, while only 4 studies provided data on long-term toxicity. Furthermore, only one out of the 147 studies involved direct clinical administration. These findings suggest that while the technology is being explored, much more data is needed regarding how these drugs perform in large-scale manufacturing and long-term safety.
Patients and providers should view these findings as a map of current research rather than a confirmation of clinical success. The study does not claim these drugs are ineffective; rather, it highlights that the evidence for their practical use in clinics is still in the early stages. More research is needed to ensure these treatments can be produced consistently and safely for patients.
